HPR50 Life-YEARS Gained with Conditional Reimbursement Access to Innovative Oncological and Hematological Medicines in Finland

Abstract

Authors

P Ihalmo S Väätäinen E Soini E Nevalainen C Vandorou P Mankinen M Price

Full Text Cite This Article
Back to Volume 25, Supplemental Issue 7S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×